KBC Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-4,887
| Closed | -$154K | – | 1843 |
|
|
2026
Q2 | $154K | Hold |
4,887
| – | – | ﹤0.01% | 1157 |
|
|
2026
Q1 | $121K | Buy |
4,887
+1,500
| +44% | +$35.7K | ﹤0.01% | 1211 |
|
|
2025
Q4 | $79K | Hold |
3,387
| – | – | ﹤0.01% | 1431 |
|
|
2025
Q3 | $67K | Hold |
3,387
| – | – | ﹤0.01% | 1510 |
|
|
2025
Q2 | $73K | Sell |
3,387
-1,312
| -28% | -$31K | ﹤0.01% | 1406 |
|
|
2025
Q1 | $114K | Hold |
4,699
| – | – | ﹤0.01% | 1407 |
|
|
2024
Q4 | $98K | Buy |
4,699
+1,542
| +49% | +$33.1K | ﹤0.01% | 1564 |
|
|
2024
Q3 | $63K | Hold |
3,157
| – | – | ﹤0.01% | 1593 |
|
|
2024
Q2 | $49K | Hold |
3,157
| – | – | ﹤0.01% | 1631 |
|
|
2024
Q1 | $50K | Hold |
3,157
| – | – | ﹤0.01% | 1557 |
|
|
2023
Q4 | $53K | Sell |
3,157
-518
| -14% | -$7.08K | ﹤0.01% | 1481 |
|
|
2023
Q3 | $43K | Sell |
3,675
-3,929
| -52% | -$52.6K | ﹤0.01% | 1561 |
|
|
2023
Q2 | $102K | Sell |
7,604
-625
| -8% | -$8.99K | ﹤0.01% | 1173 |
|
|
2023
Q1 | $136K | Hold |
8,229
| – | – | ﹤0.01% | 1098 |
|
|
2022
Q4 | $153K | Hold |
8,229
| – | – | ﹤0.01% | 1055 |
|
|
2022
Q3 | $106K | Buy |
+8,229
| New | +$97.5K | ﹤0.01% | 1160 |
|
Other funds holding CPRX
KBC Group's CPRX Position: Q3 2026 in Review
KBC Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 4,887 shares — an estimated $154K sold.
KBC Group first reported a position in CPRX in Q3 2022 and held it in 16 quarters. The position peaked at $154K in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.
- KBC Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
- KBC Group sold 4,887 Catalyst Pharmaceutical shares in Q3 2026, an estimated $154K.
- KBC Group first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 16 quarters.
- KBC Group's Catalyst Pharmaceutical position peaked at $154K in Q2 2026.
- 1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.
Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.